Acousia Therapeutics’ Clinical Trial to Address Hearing Loss from Cisplatin
Acousia Therapeutics received approval for its Phase 2 clinical trial of the otoprotectant ACOU085 for cisplatin-induced hearing loss.
Acousia Therapeutics received approval for its Phase 2 clinical trial of the otoprotectant ACOU085 for cisplatin-induced hearing loss.
Two Washington State University (WSU) researchers want to help pharmaceutical companies know if their drugs may cause hearing loss before they hit the market, according to an article on the WSU website.
Nearly 6 million patients globally are diagnosed with a cancer each year in which first-line therapy potentially includes highly toxic, platinum-based chemotherapies. While the treatment may lead to hearing loss, ringing in the ears, numbness in hands and feet, and other side effects, it is the only proven cure for the vast majority of testicular cancer patients.
SENS-401 is under development in the treatment of Sudden Sensorineural Hearing Loss (or SSNHL).
Read More“Our multiple presentations at ARO demonstrate our broad pipeline in neurotology with data presented in support of our product candidates for Ménière’s disease, tinnitus, hearing loss, and otoprotection,” said Kathie Bishop, PhD, chief scientific officer of Otonomy.
Read MoreUConn otolaryngologist Kourosh Parham and his colleagues report in “Hearing Research” that levels of prestin, a protein found only in cells in the inner ear, rise sharply when those cells are damaged and start to die.
Read MoreSince 2016, the Ida Institute Research Committee has awarded research grants to projects that investigate the outcomes of using Ida Institute methods and tools and develop evidence to show the effect of person-centered hearing care.
Read MoreThis half-day event follows the Food and Drug Administration’s (FDA) model for externally-led Patient Focused Drug Development meetings and serves to inform the agency’s regulatory decision-making in pediatric oncology.
Read MoreThe randomized, double-blind, placebo-controlled Phase 2 study will be conducted across 50 sites in Europe, the US, Canada, Israel, and Turkey, and enroll approximately 260 patients.
Read MoreThe study showed that STS administered six hours after Cisplatin could reduce the severity of hearing loss without affecting the chance of cure for the cancer.
Read MoreAccording to the FDA, Breakthrough Therapy designation is given when preliminary clinical evidence has been provided to show that a treatment effect may represent substantial improvement over available therapies for the treatment of a serious condition.
Read MoreUsing a new technique to deliver steroids to the inner ear, developed with funding from Action on Hearing Loss, Otomagnetics has been able to reduce hearing loss in mice treated with the chemotherapy drug cisplatin by 50%.
Read MoreThe drug is a therapy in development for the treatment of hearing disorders, for the prevention of Platinum-Induced Ototoxicity in pediatric patients.
Read MoreSound Pharmaceuticals announced that the company has been awarded up to $1.6 million for their development of a drug used to treat ototoxicity in patients with cystic fibrosis.
Read MoreOtonomy has announced the enrollment of the first patients in a Phase 2 clinical trial evaluating OTO-104 for the prevention of hearing loss in cancer patients undergoing chemotherapy with platinum-based agents.
Read MoreSiemens Hearing Instruments, Inc. has announced partnerships with the Pediatric Brain Tumor Foundation (PBTF) and CancerCare® to bring top-of-the-line hearing aids and audiology services to cancer patients across the country.
Read More